Federation des caisses Desjardins du Quebec Decreases Stock Holdings in DaVita Inc. $DVA

Key Points

• The Federation des caisses Desjardins du Quebec reduced its holdings in DaVita Inc. by 12.7%, owning 19,877 shares worth approximately $3,041,000 as of the latest SEC filing.
• Insider James O. Hearty sold 2,351 shares of DaVita stock for around $352,650, reducing his ownership by 8.28%.
• Analysts have a consensus rating of "Hold" for DaVita shares, with a target price of $164.00, while the company reported earnings that exceeded expectations at $2.95 per share.

Federation des caisses Desjardins du Quebec reduced its stake in shares of DaVita Inc. (NYSE:DVA - Free Report) by 12.7% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 19,877 shares of the company's stock after selling 2,886 shares during the period. Federation des caisses Desjardins du Quebec's holdings in DaVita were worth $3,041,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Fifth Third Bancorp lifted its position in shares of DaVita by 5.0% during the 1st quarter. Fifth Third Bancorp now owns 4,274 shares of the company's stock valued at $654,000 after buying an additional 204 shares in the last quarter. Concurrent Investment Advisors LLC purchased a new position in DaVita in the 1st quarter worth approximately $223,000. Wealth Enhancement Advisory Services LLC lifted its holdings in DaVita by 22.5% in the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 4,351 shares of the company's stock worth $666,000 after purchasing an additional 800 shares in the last quarter. Envestnet Asset Management Inc. lifted its holdings in DaVita by 7.9% in the 1st quarter. Envestnet Asset Management Inc. now owns 55,255 shares of the company's stock worth $8,452,000 after purchasing an additional 4,048 shares in the last quarter. Finally, OneDigital Investment Advisors LLC purchased a new position in DaVita in the 1st quarter worth approximately $200,000. 90.12% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other DaVita news, insider James O. Hearty sold 2,351 shares of the company's stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $150.00, for a total value of $352,650.00. Following the transaction, the insider owned 26,038 shares of the company's stock, valued at $3,905,700. This represents a 8.28% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 1.50% of the stock is owned by company insiders.

DaVita Trading Down 3.2%

NYSE:DVA traded down $4.33 during midday trading on Wednesday, hitting $132.38. 324,367 shares of the company traded hands, compared to its average volume of 850,406. The firm's fifty day moving average is $139.04 and its 200-day moving average is $141.73. DaVita Inc. has a 12-month low of $126.07 and a 12-month high of $179.60. The firm has a market capitalization of $9.47 billion, a P/E ratio of 13.02, a P/E/G ratio of 0.96 and a beta of 1.13. The company has a current ratio of 1.39, a quick ratio of 1.34 and a debt-to-equity ratio of 23.18.

DaVita (NYSE:DVA - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The company reported $2.95 earnings per share for the quarter, beating the consensus estimate of $2.70 by $0.25. The company had revenue of $3.38 billion for the quarter, compared to analyst estimates of $3.36 billion. DaVita had a return on equity of 369.39% and a net margin of 6.35%.DaVita's quarterly revenue was up 6.1% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.00 EPS. DaVita has set its FY 2025 guidance at 10.200-11.300 EPS. On average, sell-side analysts predict that DaVita Inc. will post 10.76 EPS for the current year.

Analyst Ratings Changes

A number of research analysts recently commented on the company. Bank of America lowered their price target on DaVita from $145.00 to $140.00 and set an "underperform" rating on the stock in a report on Wednesday. Truist Financial set a $148.00 price target on DaVita in a report on Friday, August 8th. Barclays lowered their price target on DaVita from $169.00 to $160.00 and set an "equal weight" rating on the stock in a report on Thursday, August 7th. Finally, Wall Street Zen raised DaVita from a "hold" rating to a "buy" rating in a research note on Friday, August 22nd. Three investment analysts have rated the stock with a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Reduce" and a consensus price target of $158.00.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.